Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review

Table 4 Assessment scores for prediction of the venous thromboembolic event-risk in cancer out-patients receiving chemotherapy, according to Khorana et al[73], Pabinger et al[75] and Verso et al[76]

Khorana score criteria[73]	Score
Primary cancer
With very high risk (pancreas, stomach) (high grade glioma1)	2
With high risk (lung, lymphoma, gynecologic, bladder, testicular)	1
Platelet count prior to chemotherapy > 350000/μL	1
Hb < 10 g/dL or ESA-application	1
Leukocyte count prior to chemotherapy > 11000/μL	1
Body mass index > 35 kg/m²	1
High risk	> 3
Vienna prediction score (additional parameters to Khorana score)[75]
D-dimer > 1.44 μg/mL	1
Soluble P-selectin > 153.1 μg/mL	1
High risk	> 4
Protecht prediction score (additional parameters to Khorana score)[76]
Cisplatin or carboplatin	1
Gemcitabine	1
High risk	> 3

¹High grade glioma are considered very high risk site of cancer in the Vienna prediction score only. ESA: Erythropoiesis stimulating agents.